Keywords: Novartis, Onbrez, Spiriva, Lung function, COPD

Novartis’ Onbrez plus Spiriva improves lung function in COPD patients

Article | 11 February 2011

Print This

Swiss drug major Novartis (NOVN: VX) yesterday announced that two Phase III studies show that patients with chronic obstructive pulmonary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in